Drug Profile
Cell-based Parkinson's disease therapy - Titan Pharmaceuticals
Alternative Names: Spheramine; TC-15Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Titan Pharmaceuticals
- Developer Bayer Schering Pharma; Titan Pharmaceuticals
- Class Antiparkinsonians; Cell therapies; Gene therapies; Neuroprotectants
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 02 Jul 2008 Suspended - Phase-II for Parkinson's disease in USA (Intrastriatal)
- 30 Apr 2008 Four-year, follow-up efficacy and safety data from a clinical trial in patients with moderate-to-advanced Parkinson's disease released by Titan Pharmaceuticals
- 19 Apr 2008 Pharmacodynamics data from a primate model of Parkinson's disease presented at the 60th Annual Meeting of the American Academy of Neurology (AAN-2008)